Chien, Yi-Han
Würthwein, Gudrun http://orcid.org/0000-0002-7617-183X
Zubiaur, Pablo http://orcid.org/0000-0002-6150-4320
Posocco, Bianca
Pena, María Ángeles http://orcid.org/0000-0003-0066-8943
Borobia, Alberto M. http://orcid.org/0000-0002-8584-3263
Gagno, Sara
Abad-Santos, Francisco http://orcid.org/0000-0002-6519-8885
Hempel, Georg http://orcid.org/0000-0002-5790-6423
Funding for this research was provided by:
Westfälische Wilhelms-Universität Münster
Article History
Received: 16 March 2022
Accepted: 20 June 2022
First Online: 14 July 2022
Declarations
:
: F. Abad-Santos have been consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Chemo, Cinfa, FAES Farma, Farmalíder, Ferrer, GlaxoSmithKline, Galenicum, Gilead, Italfarmaco, Janssen-Cilag, Kern Pharma, Normon, Novartis, Servier, Silverpharma, Teva and Zambon. G. Hempel serves as a consultant for AbbVie Canada. The authors declare that they have no conflict of interest.
: All procedures on healthy volunteers were performed at Clinical Research and Clinical Trials Unit (Hospital La Paz, Madrid, Spain) and Alicante Clinical Trials Unit (Department of Health Alicante-General Hospital, Alicante, Spain). The study was approved by the local ethics committees and carried out in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study on patient population was conducted at Centro di Riferimento Oncologico di Aviano (CRO, Italy) and approved by the local ethics committee and by Agenzia Italiana del Farmaco (AIFA), EudraCT number: 2017-002437-36. It was conducted according to the principles expressed in the Declaration of Helsinki and all blood samples for the present study were collected only after the signature of the informed consent from all the enrolled patients.
: Informed consent was obtained from all individual participants included in the study.